ADC Therapeutics Announces New Employee Inducement Grant
PR Newswire•02/11/2026•16:05 ET
0
Key Highlights
- ➤17,000-share option grant awarded to new employee as employment inducement
- ➤Options vest 25% after one year, then monthly through fourth anniversary
- ➤ZYNLONTA remains ADC Therapeutics’ lead commercial-stage antibody-drug conjugate
ADC Therapeutics Announces New Employee Inducement Grant PR Newswire
LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on November 2, 2026. ("Grant").
Get started
Create a free account to read the full story.